Poolbeg Pharma said on Tuesday that the US Patent and Trademarks Office has indicated that it is likely to accept the company’s application to expand its intellectual property protections around its lead asset, a drug called POLB 001.
Mostly aimed at treating severe influenza, the clinical late-stage pharmaceutical company – which spun out from Open Orphan in 2021 – received UK regulatory approval in July to proceed with human clinical trials of the drug.
While London-listed Poolbeg already holds European and US patents for the drug for the treatment of flu, POLB 001 has other potential uses, including the treatment of hypercytokinemia.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
